--- a
+++ b/clusters/9knumclustersv2/clust_1201.txt
@@ -0,0 +1,63 @@
+Clinical evidence of transformation to a more aggressive subtype of lymphoma
+History of transformation of indolent disease to DLBCL (expansion-phase only)
+Histologically confirmed, biopsy-proven diagnosis of DLBCL, BCLu, HGBCL, or TiNHL. Richter's transformation from Chronic Lymphocytic Leukemia (CLL) is not eligible.
+Richter's transformation from CLL
+Richters transformation confirmed by biopsy
+History of Richter's transformation from CLL
+CLL WITH RICHTER's TRANSFORMATION (ARM C) ONLY
+Presence of more than % pro-lymphocytes in peripheral blood; patients with Richter's transformation are not excluded
+Known histological transformation to an aggressive lymphoma
+Richter's transformation confirmed by biopsy
+Active Richters transformation
+Known histological transformation to an aggressive lymphoma (ie, Richter transformation). Note: Biopsy documentation of the absence or presence of transformation is not required.
+For patients with Richters transformation, one prior line of therapy for either CLL or Richters transformation (RT) is required
+Richter transformation.
+Richter transformation
+Patients with previously treated CLL and biopsy-proven Richters transformation with diffuse large B-cell lymphoma (DLBCL) histology according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (Richter Transformation - RT) and CD positive by flow cytometry OR immunohistochemistry.
+Richters transformation confirmed by biopsy
+CLL patients with known or suspected transformed disease (i.e. Richters transformation)\r\n* Note: biopsy proven absence of transformation is not required
+Large cell transformation
+Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
+Participants with CLL or DLBCL who have Richter's Transformation
+Evidence ongoing transformation into aggressive NHL
+CLL patients with active transformed disease (Richters transformation) are ineligible for enrollment on this study
+Known histological transformation from CLL to an aggressive lymphoma (Richter's)
+Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)
+If the subjects has Richter's Syndrome (RS), the diagnosis is confirmed by biopsy and is immunohistologically characterized as transformation to DLBCL.
+Known histological transformation from iNHL or CLL to an aggressive form of non-Hodgkin lymphoma (ie, Richter transformation) except if the CLL patient is enrolling in the B-cell receptor (BCR) previously treated cohort
+Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
+Evidence of disease transformation at the time of study entry
+Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
+Presence of more than % pro-lymphocytes in peripheral blood; patients with Richters transformation are not excluded
+History of transformation of indolent disease to DLBCL
+Active Richters transformation
+Cohort B-: ) Histologically-confirmed Richter syndrome defined as transformation of CLL or SLL into an aggressive lymphoma ) Previously treated with at least one line of standard, systemic chemotherapy or not eligible for standard therapy ) At least  measurable site of disease based on the Revised Response Criteria for Malignant Lymphoma
+Transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)
+Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
+Transformation of CLL to aggressive Non-Hodgkin's lymphoma (Richter's transformation or pro-lymphocytic leukemia)
+Subject has developed Richter's transformation confirmed by biopsy
+Transformation of CLL to aggressive non-Hodgkin lymphoma or central nervous system (CNS) involvement by CLL
+Subjects with Richter's transformation
+Known central nervous system leukemia/lymphoma or Richter's transformation
+Presence of disease transformation from a previously diagnosed low-grade lymphoma
+CLL patients with transformed disease (Richter's transformation) are ineligible for enrollment on this study
+Follicular lymphoma with histology documented by the participating institution (grades ,  or a)\r\n* For subjects with presumptive evidence of transformation based on clinical assessment of factors such as, but not limited to, increasing lactate dehydrogenase (LDH), rapidly worsening disease, or frequent B-symptoms, a pre-treatment biopsy is required to rule out large cell transformation
+Subjects with known SCLC transformation
+CLL transformation
+Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
+Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
+Richter's transformation, arising in the setting of prior CLL, documented by histologically confirmed lymphoma, including large B-cell and immunoblastic variants.
+Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
+Patients with B-CLL (not in Richters transformation) with measurable disease
+History of transformation of indolent disease to DLBCL
+Active disease transformation (ie, Richter's Syndrome); subjects with Richter's Syndrome that has resolved >  years from signing the ICD are eligible.
+Evidence of aggressive or highly aggressive lymphoma or Richters transformation based on WHO/REAL classification criteria()
+Pathologic evidence of malignant transformation
+History of transformation of indolent disease to DLBCL
+Known transformation of CLL (e.g. Richter's).
+Known transformation to an aggressive B-cell malignancy.
+Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
+Patients with Richters transformation are not allowed in the study
+Patients with the Hodgkin variant transformation of CLL will be excluded
+Known histological transformation from iNHL to diffuse large B-cell lymphoma or Richters transformation for CLL
+Richter's transformation or CLL transformation to aggressive lymphoma